varenicline + placebo

Phase 2/3Terminated
0 watching 0 views this week๐Ÿ“ˆ Rising
64
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Friedreich's Ataxia

Conditions

Friedreich's Ataxia

Trial Timeline

May 1, 2009 โ†’ May 1, 2010

About varenicline + placebo

varenicline + placebo is a phase 2/3 stage product being developed by Pfizer for Friedreich's Ataxia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00803868. Target conditions include Friedreich's Ataxia.

Hype Score Breakdown

Clinical
22
Activity
15
Company
9
Novelty
7
Community
8

Clinical Trials (20)

NCT IDPhaseStatus
NCT02856581Phase 3Terminated
NCT01934023Phase 2Completed
NCT01850953ApprovedCompleted
NCT01639560ApprovedCompleted
NCT01244061ApprovedCompleted
NCT01078298ApprovedCompleted
NCT01071187Phase 2UNKNOWN
NCT01010204ApprovedCompleted
NCT00992771Phase 2Completed
NCT00918307Phase 3Completed
NCT00977249Phase 2/3UNKNOWN
NCT00744978Phase 2Completed
NCT00803868Phase 2/3Terminated
NCT00835900Phase 2Completed
NCT00944554ApprovedCompleted
NCT00749944ApprovedCompleted
NCT00747643Pre-clinicalCompleted
NCT00937508ApprovedUNKNOWN
NCT00595868Phase 2Completed
NCT00602927Pre-clinicalCompleted

Competing Products

11 competing products in Friedreich's Ataxia

See all competitors
ProductCompanyStageHype Score
Interferon ฮณ-1bAmgenPhase 3
76
interferon ฮณ-1bAmgenPhase 3
76
Interferon ฮณ-1b + PlaceboAmgenPhase 3
76
Lu AA24493 + PlaceboLundbeckPhase 2
49
OmeveloxoloneBiogenPre-clinical
20
Placebo + EPI-743 400 mg + EPI-743 200 mgPTC TherapeuticsPhase 2
49
SGT-212Solid BiosciencesPhase 1
25
idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69
Idebenone + Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69
IdebenoneSanthera PharmaceuticalsPhase 3
69
Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69